Simon Van Haren Email & Phone Number | Simon van Haren’s research is focused on better understanding the molecular basis of age-specific immune responses to vaccines. Understanding how the human immune system changes with age in how it responds to vaccination can ultimately inform the development of novel vaccines to provide early life protection against pathogens such as Respiratory Syncytial Virus (RSV). A major area of his research is to dissect the molecular mechanism of adjuvants. Adjuvants are key vaccine components capable of instructing different types of immune responses. Supported by an Early Career Award from the Thrasher Research Fund, he completed a project that aims to identify combinations of Toll-like receptor (TLR) and C-type lectin receptor (CLR) agonists that could overcome the classical impairment in CD4+ T cell-polarization seen in newborns. This study has identified novel age-dependent synergy between specific TLR and CLR adjuvant combinations, which are currently under evaluation for their ability to enhance early life immunity against RSV. The second major area of Dr. van Haren’s research is the study of antigen presentation and the effect of vaccine adjuvants on this process. Dr. van Haren has developed a portfolio of mass-spectrometry techniques and cell culture platforms that can be used to study the ability of vaccine adjuvants, or combinations, to enhance the presentation of vaccine antigens on MHC class II or to induce antigen cross-presentation on MHC class I. The ability to induce cross-presentation and subsequently induce a CD8+ T cell response is key for developing immunity against intracellular pathogens such as RSV or Influenza. Dr. van Haren has modeled the immune systems of newborns, 6-month old infants, adults, and elderly individuals in different in vitro settings, such as whole blood, monocytes, monocyte-derived DCs, B-and T-cells and a microphysiological tissue construct. Using state-of-the-art mass-spectrometry and cell biology techniques he aims to unravel the ontogeny of the human immune response to vaccines at the molecular level, with the goal to provide novel insights relevant to future vaccine development.

Simon Van Haren

Simon van Haren’s research is focused on better understanding the molecular basis of age-specific im...
Greater Boston, Greater Boston, United States

*50 free lookup(s) per month.

No credit card required.

Simon Van Haren’s Email simon.vanharen@childrenshospital.org

Simon Van Haren’s Phone Numbers

Get SIMON’s Phone Number (For Free)

Social Media

Simon Van Haren’s Location Greater Boston, Greater Boston, United States

Simon Van Haren’s Current Industry Harvard Medical School Boston Childrens Hospital Childrens Hospital Boston

Simon Van Haren’s Prior Industry Sanquin Research

Not the Simon Van Haren you were looking for?

Find accurate emails & phone numbers for over 700M professionals.

Work Experience

Harvard Medical School

Assistant Professor of Pediatrics at Harvard Medical School

2024-01-01T00:00:00.000Z - Present

Boston Childrens Hospital

Research Associate

2018-11-01T00:00:00.000Z - Present

Childrens Hospital Boston

Postdoctoral fellow

2012-03-01T00:00:00.000Z - Present

Sanquin Research

PhD student

2006-01-01T00:00:00.000Z - 2011-01-01T00:00:00.000Z

Skills

No Skills Available

Languages

No Languages Available

FAQ About Simon Van Haren

Simon Van Haren is located at
Greater Boston, Greater Boston, United States

Simon Van Haren is a Simon van Haren’s research is focused on better understanding the molecular basis of age-specific immune responses to vaccines. Understanding how the human immune system changes with age in how it responds to vaccination can ultimately inform the development of novel vaccines to provide early life protection against pathogens such as Respiratory Syncytial Virus (RSV). A major area of his research is to dissect the molecular mechanism of adjuvants. Adjuvants are key vaccine components capable of instructing different types of immune responses. Supported by an Early Career Award from the Thrasher Research Fund, he completed a project that aims to identify combinations of Toll-like receptor (TLR) and C-type lectin receptor (CLR) agonists that could overcome the classical impairment in CD4+ T cell-polarization seen in newborns. This study has identified novel age-dependent synergy between specific TLR and CLR adjuvant combinations, which are currently under evaluation for their ability to enhance early life immunity against RSV. The second major area of Dr. van Haren’s research is the study of antigen presentation and the effect of vaccine adjuvants on this process. Dr. van Haren has developed a portfolio of mass-spectrometry techniques and cell culture platforms that can be used to study the ability of vaccine adjuvants, or combinations, to enhance the presentation of vaccine antigens on MHC class II or to induce antigen cross-presentation on MHC class I. The ability to induce cross-presentation and subsequently induce a CD8+ T cell response is key for developing immunity against intracellular pathogens such as RSV or Influenza. Dr. van Haren has modeled the immune systems of newborns, 6-month old infants, adults, and elderly individuals in different in vitro settings, such as whole blood, monocytes, monocyte-derived DCs, B-and T-cells and a microphysiological tissue construct. Using state-of-the-art mass-spectrometry and cell biology techniques he aims to unravel the ontogeny of the human immune response to vaccines at the molecular level, with the goal to provide novel insights relevant to future vaccine development.

Simon Van Haren currently works in the Harvard Medical School | Boston Childrens Hospital | Childrens Hospital Boston |

No Languages Available

Simon Van Haren has prior
experience in the following industries:
Sanquin Research

Simon Van Haren has the following professional experience:
Harvard Medical School | Boston Childrens Hospital | Childrens Hospital Boston | Sanquin Research